针对高风险个体和全人群的糖尿病预防干预的成本效益:系统综述
该系统综述纳入2008至2017年发表的39项研究,评估针对2型糖尿病高风险个体及全人群的预防干预的成本效益。结果显示,高风险个体的生活方式和二甲双胍干预均具成本效益,全人群中糖饮税可节省成本,其他人群干预结果不一致。
要点
- 高风险个体生活方式干预中位ICER为12,510美元/QALY,二甲双胍为17,089美元/QALY。
- 遵循DPP课程的生活方式干预中位ICER为6,212美元/QALY,低于未遵循者的13,228美元/QALY。
- 全人群中糖饮税从医疗系统和政府角度均节省成本,其他人群干预结果不一致。
核心结论
- 本综述纳入的大多数2型糖尿病预防干预具有成本效益或节省成本。
- 研究结果可帮助决策者在真实世界中设定2型糖尿病预防的优先事项和分配资源。
研究设计与样本
- 系统检索7个电子数据库,纳入2008至2017年发表的英文研究,共39项。
- 其中28项针对高风险个体,11项针对全人群。
- 高风险个体干预分为生活方式和二甲双胍,生活方式干预按实施方法和人员类型分组。
- 采用中位增量成本效果比(ICER)衡量成本效益,以每质量调整生命年(QALY)成本或节省成本表示,ICER以2017年美元报告。
- 使用50,000美元/QALY阈值判断干预是否具有成本效益。
主要发现
- 高风险个体中,与无干预相比,生活方式干预中位ICER为12,510美元/QALY,二甲双胍干预为17,089美元/QALY。
- 生活方式干预中,遵循糖尿病预防计划(DPP)课程者中位ICER为6,212美元/QALY,未遵循者为13,228美元/QALY。
- 与一对一或由卫生专业人员提供的生活方式干预相比,小组形式或卫生专业人员与非专业卫生工作者联合提供的干预ICER更低。
- 全人群干预中,对含糖饮料征税从医疗系统和政府角度均节省成本。
- 其他全人群干预(包括果蔬补贴、社区教育项目和建筑环境改造)的评估结果不一致。
关键数值与推荐
- 成本效益判定阈值为50,000美元/QALY。
- 高风险个体生活方式干预中位ICER为12,510美元/QALY,二甲双胍为17,089美元/QALY。
- 遵循DPP课程的生活方式干预中位ICER为6,212美元/QALY,未遵循者为13,228美元/QALY。
- 含糖饮料税从医疗系统和政府角度均节省成本。
临床怎么用
- 在高风险个体中,生活方式干预和二甲双胍干预均可考虑作为具有成本效益的预防策略。
- 优先选择遵循DPP课程、小组形式或由卫生专业人员与非专业卫生工作者联合提供的生活方式干预,因其ICER更低。
- 全人群中可优先考虑含糖饮料税,因其可节省成本;其他人群干预需根据本地证据谨慎决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We conducted a systematic review of studies evaluating the cost-effectiveness (CE) of interventions to prevent type 2 diabetes (T2D) among high-risk individuals and whole populations. RESEARCH DESIGN AND METHODS: Interventions targeting high-risk individuals are those that identify people at high risk of developing T2D and then treat them with either lifestyle or metformin interventions. Population-based prevention strategies are those that focus on the whole population regardless of the level of risk, creating public health impact through policy implementation, campaigns, and other environmental strategies. We systematically searched seven electronic databases for studies published in English between 2008 and 2017. We grouped lifestyle interventions targeting high-risk individuals by delivery method and personnel type. We used the median incremental cost-effectiveness ratio (ICER), measured in cost per quality-adjusted life year (QALY) or cost saved to measure the CE of interventions. We used the $50,000/QALY threshold to determine whether an intervention was cost-effective or not. ICERs are reported in 2017 U.S. dollars. RESULTS: Our review included 39 studies: 28 on interventions targeting high-risk individuals and 11 targeting whole populations. Both lifestyle and metformin interventions in high-risk individuals were cost-effective from a health care system or a societal perspective, with median ICERs of $12,510/QALY and $17,089/QALY, respectively, compared with no intervention. Among lifestyle interventions, those that followed a Diabetes Prevention Program (DPP) curriculum had a median ICER of $6,212/QALY, while those that did not follow a DPP curriculum had a median ICER of $13,228/QALY. Compared with lifestyle interventions delivered one-on-one or by a health professional, those offered in a group setting or provided by a combination of health professionals and lay health workers had lower ICERs. Among population-based interventions, taxing sugar-sweetened beverages was cost-saving from both the health care system and governmental perspectives. Evaluations of other population-based interventions-including fruit and vegetable subsidies, community-based education programs, and modifications to the built environment-showed inconsistent results. CONCLUSIONS: Most of the T2D prevention interventions included in our review were found to be either cost-effective or cost-saving. Our findings may help decision makers set priorities and allocate resources for T2D prevention in real-world settings.
引用
- Zhou X, Siegel KR, Ng BP, et al. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review. Diabetes Care. 2020. PMID: 33534726. doi:10.2337/dci20-0018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。